The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature

Journal of Immunology

Volumn 179, Issue 8, 2007, Pages 5346-5357

  Tritto, Elaine ^a   Muzzi, Alessandro ^a   Pesce, Isabella ^a   Monaci, Elisabetta ^a   Nuti, Sandra ^a   Galli, Grazia ^a   Wack, Andreas ^a   Rappuoli, Rino ^a   Hussell, Tracy ^b   De Gregorio, Ennio ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOLOGICAL ADJUVANT; LTK 63; LTK63; UNCLASSIFIED DRUG; BACTERIAL TOXIN; ENTEROTOXIN; ENTEROTOXIN LT; ESCHERICHIA COLI PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL CYCLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENOME IMPRINTING; GRANULOCYTE; HOST RESISTANCE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; LYMPHOCYTE MIGRATION; MACROPHAGE ACTIVATION; MOUSE; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT MUCOSA; SCID MOUSE; T LYMPHOCYTE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MOTION; CYTOLOGY; ENDOTRACHEAL INTUBATION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; LUNG; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE MUTANT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; B-LYMPHOCYTE SUBSETS; BACTERIAL TOXINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CHEMOKINES; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNITY, NATURAL; INTUBATION, INTRATRACHEAL; LUNG; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; TRANSCRIPTION, GENETIC;

EID: 38449108512     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.8.5346     Document Type: Article

References (43)

1. Zhang, P., W. R. Summer, G. J. Bagby, and S. Nelson. 2000. Innate immunity and pulmonary host defense. Immunol. Rev. 173: 39-51.
2. Freytag, L. C., and J. D. Clements. 2005. Mucosal adjuvants. Vaccine 23: 1804-1813.
3. Holmgren, J., J. Adamsson, F. Anjuere, J. Clemens, C. Czerkinsky, K. Eriksson, C. F. Flach, A. George-Chandy, A. M. Harandi, M. Lebens, et al. 2005. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol. Lett. 97: 181-188.
4. Klinman, D. M. 2004. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4: 249-258.
5. Fukuta, S., J. L. Magnani, E. M. Twiddy, R. K. Holmes, and V. Ginsburg. 1988. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect. Immun. 56: 1748-1753.
6. Rappuoli, R., M. Pizza, G. Douce, and G. Dougan. 1999. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today 20: 493-500.
7. Marinaro, M., A. Riccomi, R. Rappuoli, M. Pizza, V. Fiorelli, A. Tripiciano, A. Cafaro, B. Ensoli, and M. T. De Magistris. 2003. Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. Vaccine 21: 3972-3981.
8. Katz, J. M., X. Lu, S. A. Young, and J. C. Galphin. 1997. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J. Infect. Dis. 175: 352-363.
9. Giuliani, M. M., G. Del Giudice, V. Giannelli, G. Dougan, G. Douce, R. Rappuoli, and M. Pizza. 1998. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187: 1123-1132.
10. Peppoloni, S., P. Ruggiero, M. Contorni, M. Morandi, M. Pizza, R. Rappuoli, A. Podda, and G. Del Giudice. 2003. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Exp. Rev. Vaccines 2: 285-293.
11. Pizza, M., M. R. Fontana, M. M. Giuliani, M. Domenighini, C. Magagnoli, V. Giannelli, D. Nucci, W. Hol, R. Manetti, and R. Rappuoli. 1994. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J. Exp. Med. 180: 2147-2153.
12. Neidleman, J. A., M. Vajdy, M. Ugozzoli, G. Ott, and D. O'Hagan. 2000. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55. Immunology 101: 154-160.
13. Baudner, B. C., M. Morandi, M. M. Giuliani, J. C. Verhoef, H. E. Junginger, P. Costantino, R. Rappuoli, and G. Del Giudice. 2004. Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. J. Infect. Dis. 189: 828-832.
14. Marchetti, M., M. Rossi, V. Giannelli, M. M. Giuliani, M. Pizza, S. Censini, A. Covacci, P. Massari, C. Pagliaccia, R. Manetti, et al. 1998. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 16: 33-37.
15. Bonenfant, C., I. Dimier-Poisson, F. Velge-Roussel, D. Buzoni-Gatel, G. Del Giudice, R. Rappuoli, and D. Bout. 2001. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii. Infect. Immun. 69: 1605-1612.
16. Jakobsen, H., S. Bjarnarson, G. Del Giudice, M. Moreau, C. A. Siegrist, and I. Jonsdottir. 2002. Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect. Immun. 70: 1443-1452.
17. Tierney, R., A. S. Beignon, R. Rappuoli, S. Muller, D. Sesardic, and C. D. Partidos. 2003. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. J. Infect. Dis. 188: 753-758.
18. Stephenson, I., M. C. Zambon, A. Rudin, A. Colegate, A. Podda, R. Bugarini, G. Del Giudice, A. Minutello, S. Bonnington, J. Holmgren, et al. 2006. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. 80: 4962-4970.
19. Waag, D. M., M. J. McCluskie, N. Zhang, and A. M. Krieg. 2006. A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect. Immun. 74: 1944-1948.
20. Edwards, L., A. E. Williams, A. M. Krieg, A. J. Rae, R. J. Snelgrove, and T. Hussell. 2005. Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner. Eur. J. Immunol. 35: 273-281.
21. Williams, A. E., L. Edwards, I. R. Humphreys, R. Snelgrove, A. Rae, R. Rappuoli, and T. Hussell. 2004. Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease. J. Immunol. 173: 7435-7443.
22. Karrer, H. E. 1958. The ultrastructure of mouse lung: the alveolar macrophage. J. Biophys. Biochem. Cytol. 4: 693-700.
23. Saal, L. H., C. Troein, J. Vallon-Christersson, S. Gruvberger, A. Borg, and C. Peterson. 2002. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol. 3: SOFTWARE0003.
24. Saeed, A. I., V. Sharov, J. White, J. Li, W. Liang, N. Bhagabati, J. Braisted, M. Klapa, T. Currier, M. Thiagarajan, et al. 2003. TM4: a free, open-source system for microarray data management and analysis. BioTechniques 34: 374-378.
25. van Rijt, L. S., H. Kuipers, N. Vos, D. Hijdra, H. C. Hoogsteden, and B. N. Lambrecht. 2004. A rapid flow cytometric method for determining the cellular composition of bronchoalveolar lavage fluid cells in mouse models of asthma. J. Immunol. Methods 288: 111-121.
26. Gonzalez-Juarrero, M., T. S. Shim, A. Kipnis, A. P. Junqueira-Kipnis, and I. M. Orme. 2003. Dynamics of macrophage cell populations during murine pulmonary tuberculosis. J. Immunol. 171: 3128-3135.
27. Bernasconi, C. F., M. L. Ragains, and S. Bhattacharya. 2003. Reactions that generate aromatic molecules: is aromatic stabilization less or more advanced than bond changes at the transition state? Kinetic and thermodynamic acidities of rhenium carbene complexes. J. Am. Chem. Soc. 125: 12328-12336.
28. Reed, L. J., and J. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27: 493-497.
29. Ugozzoli, M., G. Santos, J. Donnelly, and D. T. O'Hagan. 2001. Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant. J. Infect. Dis. 183: 351-354.
30. Di Tommaso, A., G. Saletti, M. Pizza, R. Rappuoli, G. Dougan, S. Abrignani, G. Douce, and M. T. De Magistris. 1996. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64: 974-979.
31. Baudner, B. C., O. Balland, M. M. Giuliani, P. Von Hoegen, R. Rappuoli, D. Betbeder, and G. Del Giudice. 2002. Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect. Immun. 70: 4785-4790.
32. Baudner, B. C., M. M. Giuliani, J. C. Verhoef, R. Rappuoli, H. E. Junginger, and G. D. Giudice. 2003. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 21: 3837-3844.
33. Bosma, G. C., R. P. Custer, and M. J. Bosma. 1983. A severe combined immunodeficiency mutation in the mouse. Nature 301: 527-530.
34. Osterholzer, J. J., T. Ames, T. Polak, J. Sonstein, B. B. Moore, S. W. Chensue, G. B. Toews, and J. L. Curtis. 2005. CCR2 and CCR6, but not endothelial selectins, mediate the accumulation of immature dendritic cells within the lungs of mice in response to particulate antigen. J. Immunol. 175: 874-883.
35. Janssens, S., and R. Beyaert. 2003. Role of Toll-like receptors in pathogen recognition. Clin. Microbiol. Rev. 16: 637-646.
36. Palaniyar, N., J. Nadesalingam, and K. B. Reid. 2002. Pulmonary innate immune proteins and receptors that interact with gram-positive bacterial ligands. Immunobiology 205: 575-594.
37. Roozendaal, R., and M. C. Carroll. 2006. Emerging patterns in complement-mediated pathogen recognition. Cell 125: 29-32.
38. Delclaux, C., and E. Azoulay. 2003. Inflammatory response to infectious pulmonary injury. Eur. Respir. J. Suppl. 42:10s-14s.
39. Jakubzick, C., F. Tacke, J. Llodra, N. van Rooijen, and G. J. Randolph. 2006. Modulation of dendritic cell trafficking to and from the airways. J. Immunol. 176: 3578-3584.
40. Walzl, G., S. Tafuro, P. Moss, P. J. Openshaw, and T. Hussell. 2000. Influenza virus lung infection protects from respiratory syncytial virus-induced immunopathology. J. Exp. Med. 192: 1317-1326.
41. + T cells in heterologous antiviral immunity and immunopathology in the lung. Nat. Immunol. 2: 1067-1076.
42. + T cell recruitment and proliferation during influenza infection. Virology 340: 296-306.
43. Roman, E., E. Miller, A. Harmsen, J. Wiley, U. H. Von Andrian, G. Huston, and S. L. Swain. 2002. CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J. Exp. Med. 196: 957-968.